Cystic echinococcosis is the metacestode stage of Echinococcus granulosus and is a worldwide public health problem. Today, various difficulties in the treatment of cystic echinococcosis limit the treatment of cystic echinococcosis. In this study, the in vitro activity of PLGA nanoparticles loaded with albendazole sulfoxide and praziquantel and targeted with phytase enzyme on Echinococcus granulosus micro-hydatid cysts was evaluated as a new formulation. For this purpose, first conjugation of PLGA polymer and phytase enzyme was performed, then albendazole sulfoxide and praziquantel loaded nanoparticles were prepared using PLGA-phytase polymer and characterization studies were performed. Permeability and cytotoxicity tests were carried out with cell culture studies of the formulations for which characterization studies were performed and it was found that the formulations did not show any cytotoxic effect. In order to evaluate the formulations, micro-hydatid cysts were developed in vitro with Echinococcus granulosus protoscoleces collected from slaughterhouse animals and the formulations were applied. In vitro hydatid cyst viability studies, approximately 50 % of cysts died on day 4 in the group applied with the combination of 10 μg/mL free albendazole sulfoxide and 50 μg/mL free praziquantel, while 100 % of cysts died in the group applied with the new formulation containing the same amount of drug. In addition, ex vivo studies on the laminar layer of hydatid cysts obtained from sheep liver showed that the new formulation binds to the laminar layer and increases the permeability of albendazole sulfoxide and praziquantel across the laminar layer by approximately 2-fold.